The following amendment has been made to the ‘Arix Bioscience plc Result of Annual General Meeting' announcement released on 23/05/2023 at 16:30 under EQS News ID 1639935.

 

Website links to the full details of the Arix investor relations website and National Storage Mechanism have been reinserted, owing to a text conversion error on the EQS platform.

 

All other information remains unchanged. The fully amended text is shown below:

 

Arix Bioscience plc

 

Result of Annual General Meeting

 

LONDON, 24 May 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's website at: https://arixbioscience.com/investor-relations/document-library?folder=AGM&year=

 

No	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	TOTAL VOTES	% of ISC VOTED	VOTES WITHHELD
1	To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2022	68,931,411	100.00%	3,441	0.00%	68,934,852	53.28%	8,440
2	To approve the Directors' Remuneration Report	61,073,950	89.25%	7,358,207	10.75%	68,432,157	52.89%	511,135
3	To re-elect Peregrine Moncreiffe as a Director	68,099,019	98.79%	834,821	1.21%	68,933,840	53.28%	9,452
4	To re-elect Maureen O'Connell as a Director	68,894,053	99.94%	42,077	0.06%	68,936,130	53.28%	7,162
5	To re-elect Isaac Kohlberg as a Director	68,900,656	99.98%	17,184	0.02%	68,917,840	53.26%	25,452
6	To re-elect Robert Lyne as a Director	68,902,689	99.95%	31,595	0.05%	68,934,284	53.28%	9,008
7	To elect Dr. Debra Barker as a Director	68,907,528	99.95%	32,248	0.05%	68,939,776	53.28%	3,516
8	To elect Andrew Smith as a Director	68,921,195	99.98%	13,089	0.02%	68,934,284	53.28%	9,008
9	To appoint BDO LLP as auditors of the Company	68,929,881	99.99%	7,445	0.01%	68,937,326	53.28%	5,966
10	To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration	68,934,245	100.00%	2,013	0.00%	68,936,258	53.28%	7,034
11	To authorise the Directors to allot shares	65,989,256	95.72%	2,950,520	4.28%	68,939,776	53.28%	3,516
12	Authority to disapply statutory pre‐ emption rights	62,199,252	90.23%	6,734.680	9.77%	68,933,932	53.28%	9,360
13	Additional authority to disapply statutory pre‐ emption rights	62,202,105	90.23%	6,731,827	9.77%	68,933,932	53.28%	9,360
14	To authorise the Company to purchase its own shares	68,921,128	99.98%	17,177	0.02%	68,938,305	53.28%	4,987
15	Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice	68,145,351	98.85%	792,954	1.15%	68,938,305	53.28%	4,987

 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed here: https://data.fca.org.uk/#/nsm/nationalstoragemechanism   

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 25 April 2023, which is available on Arix investor relations website at: https://arixbioscience.com/investor-relations/document-library?folder=AGM&year=

[ENDS]

 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com